J T Hartmann
Overview
Explore the profile of J T Hartmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
2516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Casali P, Le Cesne A, Velasco A, Kotasek D, Rutkowski P, Hohenberger P, et al.
Ann Oncol
. 2021 Jan;
32(4):533-541.
PMID: 33482247
Background: In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk gastrointestinal stromal tumors (GIST) patients. Interim analysis results...
2.
Folprecht G, Gruenberger T, Bechstein W, Raab H, Weitz J, Lordick F, et al.
Ann Oncol
. 2014 Mar;
25(5):1018-25.
PMID: 24585720
Background: Initially, unresectable colorectal liver metastases can be resected after response to chemotherapy. While cetuximab has been shown to increase response and resection rates, the survival outcome for this conversion...
3.
Keus R, Nout R, Blay J, de Jong J, Hennig I, Saran F, et al.
Ann Oncol
. 2013 Jul;
24(10):2672-2676.
PMID: 23868907
Background: To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out. Materials And Methods: Patients with inoperable progressive...
4.
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al.
Ann Oncol
. 2012 Nov;
24(4):878-88.
PMID: 23152360
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings in 2003 (Essen,...
5.
Massard C, Kramar A, Beyer J, Hartmann J, Lorch A, Pico J, et al.
Ann Oncol
. 2012 Oct;
24(2):322-328.
PMID: 23104726
Background: An early serum tumor marker (TM) decline during chemotherapy was shown to independently predict survival in patients with poor-prognosis disseminated non-seminomatous germ-cell tumors (NSGCTs). The aim of this study...
6.
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, et al.
Invest New Drugs
. 2012 Jul;
31(3):661-8.
PMID: 22832803
Matuzumab is a humanized IgG1 EGFR monoclonal antibody. This phase I study investigated the tolerability, safety and pharmacokinetics (PK) of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced...
7.
Hartmann J, Bauer S, Egerer G, Horger M, Kopp H, Grunwald V, et al.
Invest New Drugs
. 2012 Jul;
31(1):167-74.
PMID: 22763609
Background: This study evaluated efficacy and safety of pemetrexed in patients with refractory soft tissue sarcoma. Methods: Patients received pemetrexed intravenously at a dose of 500 mg/m² every 21 days...
8.
Al-Batran S, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, et al.
Ann Oncol
. 2011 Nov;
23(7):1699-705.
PMID: 22112973
Background: The prognostic role of matrix metalloproteinase-9 (MMP-9) in metastatic gastric cancer has not been validated. Patients And Methods: We carried out a molecular analysis in 222 metastatic gastric cancer...
9.
Schlemmer M, Bauer S, Schutte R, Hartmann J, Bokemeyer C, Hosius C, et al.
Eur J Med Res
. 2011 Jul;
16(5):206-12.
PMID: 21719393
Gastrointestinal stromal tumors (GIST) are mesenchymal tumors that in the past were classified as leiomyosarcomas or leiomyomas not responding to standard sarcoma chemotherapy. In several phase I and II trials...
10.
Moehler M, Mueller A, Hartmann J, Ebert M, Al-Batran S, Reimer P, et al.
Eur J Cancer
. 2011 May;
47(10):1511-20.
PMID: 21561763
Background: Sunitinib monotherapy in pretreated patients with advanced gastric cancer (AGC) was investigated. Preplanned analyses of tumour biomarkers on treatment outcome were performed. Patients And Methods: Patients received sunitinib 50mg/day...